Literature DB >> 19273578

AMP-activated protein kinase response to contractions and treatment with the AMPK activator AICAR in young adult and old skeletal muscle.

D M Thomson1, J D Brown, N Fillmore, S K Ellsworth, D L Jacobs, W W Winder, C A Fick, S E Gordon.   

Abstract

One characteristic of ageing skeletal muscle is a decline in mitochondrial function. Activation of AMP-activated protein kinase (AMPK) occurs in response to an increased AMP/ATP ratio, which is one potential result of mitochondrial dysfunction. We have previously observed higher AMPK activity in old (O; 30 months) vs young adult (YA; 8 months) fast-twitch muscle in response to chronic overload. Here we tested the hypothesis that AMPK would also be hyperactivated in O vs YA fast-twitch extensor digitorum longus muscles from Fischer(344) x Brown Norway (FBN) rats (n = 8 per group) in response to high-frequency electrical stimulation of the sciatic nerve (HFES) or injection of AICAR, an activator of AMPK. Muscles were harvested immediately after HFES (10 sets of six 3-s contractions, 10 s rest between contractions, 1 min rest between sets) or 1 h after AICAR injection (1 mg (g body weight)(-1) subcutaneously). The phosphorylations of AMPKalpha and acetyl-CoA carboxylase (ACC2; a downstream AMPK target) were both greatly increased (P <or= 0.05) in response to HFES in O muscles, but were either unresponsive (AMPK alpha) or much less responsive (ACC) in YA muscles. AMPK alpha2 activity was also greatly elevated in response to HFES in O muscles (but not YA muscles) despite a lower total AMPK alpha2 protein content in O vs YA muscles. In contrast, AMPK alpha2 activity was equally responsive to AICAR treatment in both age groups. Since mitochondrial content and/or efficiency could potentially underlie AMPK hyperactivation, we measured levels of mitochondrial proteins as well as citrate synthase (CS) activity. While CS activity was increased by 25% in O vs YA muscles, uncoupling protein-3 (UCP-3) protein level was upregulated with age by 353%. Thus, AMPK hyperactivation in response to contractile activity in aged fast-twitch muscle may be the result of compromised cellular energetics and not necessarily due to an inherent defect in responsiveness of the AMPK molecule per se.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273578      PMCID: PMC2689345          DOI: 10.1113/jphysiol.2008.166512

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  57 in total

1.  Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle.

Authors:  W Derave; H Ai; J Ihlemann; L A Witters; S Kristiansen; E A Richter; T Ploug
Journal:  Diabetes       Date:  2000-08       Impact factor: 9.461

2.  Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase.

Authors:  Marianne Suter; Uwe Riek; Roland Tuerk; Uwe Schlattner; Theo Wallimann; Dietbert Neumann
Journal:  J Biol Chem       Date:  2006-08-30       Impact factor: 5.157

3.  Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation.

Authors:  P J Atherton; J Babraj; K Smith; J Singh; M J Rennie; H Wackerhage
Journal:  FASEB J       Date:  2005-02-16       Impact factor: 5.191

4.  Reduced mitochondrial coupling in vivo alters cellular energetics in aged mouse skeletal muscle.

Authors:  David J Marcinek; Kenneth A Schenkman; Wayne A Ciesielski; Donghoon Lee; Kevin E Conley
Journal:  J Physiol       Date:  2005-10-27       Impact factor: 5.182

5.  Decline in skeletal muscle mitochondrial function with aging in humans.

Authors:  Kevin R Short; Maureen L Bigelow; Jane Kahl; Ravinder Singh; Jill Coenen-Schimke; Sreekumar Raghavakaimal; K Sreekumaran Nair
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-30       Impact factor: 11.205

6.  Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle.

Authors:  W W Winder; B F Holmes; D S Rubink; E B Jensen; M Chen; J O Holloszy
Journal:  J Appl Physiol (1985)       Date:  2000-06

7.  Alterations in mitochondrial function, hydrogen peroxide release and oxidative damage in mouse hind-limb skeletal muscle during aging.

Authors:  Abdellah Mansouri; Florian L Muller; Yuhong Liu; Rainer Ng; John Faulkner; Michelle Hamilton; Arlan Richardson; Ting-Ting Huang; Charles J Epstein; Holly Van Remmen
Journal:  Mech Ageing Dev       Date:  2006-01-06       Impact factor: 5.432

8.  Phosphorylation of p70(S6k) correlates with increased skeletal muscle mass following resistance exercise.

Authors:  K Baar; K Esser
Journal:  Am J Physiol       Date:  1999-01

9.  The Fischer 344/NNiaHSd X Brown Norway/BiNia is a better model of sarcopenia than the Fischer 344/NNiaHSd: a comparative analysis of muscle mass and contractile properties in aging male rat models.

Authors:  Kevin M Rice; Jon K Linderman; Randy S Kinnard; Eric R Blough
Journal:  Biogerontology       Date:  2005       Impact factor: 4.277

10.  Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction.

Authors:  Kei Sakamoto; Afshan McCarthy; Darrin Smith; Kevin A Green; D Grahame Hardie; Alan Ashworth; Dario R Alessi
Journal:  EMBO J       Date:  2005-05-05       Impact factor: 11.598

View more
  14 in total

1.  Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes.

Authors:  Xianmin Xu; Satoru Kobayashi; Kai Chen; Derek Timm; Paul Volden; Yuan Huang; James Gulick; Zhenyu Yue; Jeffrey Robbins; Paul N Epstein; Qiangrong Liang
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

2.  Impaired AMPK Activity Drives Age-Associated Acute Lung Injury after Hemorrhage.

Authors:  Brian D Southern; Rachel G Scheraga; Mitchell A Olman
Journal:  Am J Respir Cell Mol Biol       Date:  2017-05       Impact factor: 6.914

3.  Reduced REDD1 expression contributes to activation of mTORC1 following electrically induced muscle contraction.

Authors:  Bradley S Gordon; Jennifer L Steiner; Charles H Lang; Leonard S Jefferson; Scot R Kimball
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

4.  Age-related anabolic resistance after endurance-type exercise in healthy humans.

Authors:  William J Durham; Shanon L Casperson; Edgar L Dillon; Michelle A Keske; Douglas Paddon-Jones; Arthur P Sanford; Robert C Hickner; James J Grady; Melinda Sheffield-Moore
Journal:  FASEB J       Date:  2010-06-14       Impact factor: 5.191

5.  Acetylation of yeast AMPK controls intrinsic aging independently of caloric restriction.

Authors:  Jin-Ying Lu; Yu-Yi Lin; Jin-Chuan Sheu; June-Tai Wu; Fang-Jen Lee; Yue Chen; Min-I Lin; Fu-Tien Chiang; Tong-Yuan Tai; Shelley L Berger; Yingming Zhao; Keh-Sung Tsai; Heng Zhu; Lee-Ming Chuang; Jef D Boeke
Journal:  Cell       Date:  2011-09-09       Impact factor: 41.582

6.  Lipogenic regulators are elevated with age and chronic overload in rat skeletal muscle.

Authors:  D A Rivas; E P Morris; R A Fielding
Journal:  Acta Physiol (Oxf)       Date:  2011-04-22       Impact factor: 6.311

7.  Reduced AMPK-ACC and mTOR signaling in muscle from older men, and effect of resistance exercise.

Authors:  Mengyao Li; Lex B Verdijk; Kei Sakamoto; Brian Ely; Luc J C van Loon; Nicolas Musi
Journal:  Mech Ageing Dev       Date:  2012-09-19       Impact factor: 5.432

8.  The effects of age and muscle contraction on AMPK activity and heterotrimer composition.

Authors:  Shalene E Hardman; Derrick E Hall; Alyssa J Cabrera; Chad R Hancock; David M Thomson
Journal:  Exp Gerontol       Date:  2014-04-18       Impact factor: 4.032

9.  Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy.

Authors:  Clàudia Cerveró; Neus Montull; Olga Tarabal; Lídia Piedrafita; Josep E Esquerda; Jordi Calderó
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 10.  Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?

Authors:  Jingmin Yang; Xiao Li; Danyan Xu
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.